Aarti PharmaQ1 FY25

Aarti Pharma Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,015.9P/E: 35.4Market Cap: ₹9.2K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • CDMO/CMO business expects strong growth of 25% to 30% year-on-year in FY25 driven by increased inquiries and projects due to US Biosecure Act and China Plus One strategies.
  • Expansion projects like Atali facility commissioning by Q4 FY25 will add 400-500 KL capacity, increasing capacity by about 25-30%, supporting future demand surge.
  • Xanthine segment capacity is being expanded to 9000 MT by early FY26, addressing demand growth.
  • Semi-commercial block at Vapi site operational in Q2 FY25 will enable small to medium batch size productions.
  • Despite competition in Xanthine prices, export share grew to 57% this quarter, indicating volume growth potential.
  • The Company aims for consolidated EBITDA growth of 10%-12% in FY25 and a long-term annual growth target of approximately 15%.
  • Multi-stage CDMO projects' growth expected as more projects move from early to commercial stages.

See what Aarti Pharma management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • The transcript does not mention any current or planned fundraising through debt or equity.
  • No specific details or discussions about raising funds via equity or debt instruments were provided during the Q1 FY25 earnings call.
  • The focus was primarily on capacity expansions (Xanthine project, Atali project) and operational updates funded through internal accruals or ongoing CAPEX plans.
  • Total CAPEX guidance for FY25 is around Rs. 500-550 crores, including Rs. 150 crores for Xanthine and Rs. 375 crores for the Atali project, with no mention of external fundraising.
  • Management has not indicated any intentions to raise additional capital through the markets as of this call.

See what Aarti Pharma management said on order book — free account, 30 seconds.

Capex plans

Yes
- **Xanthine Expansion:** Approx. Rs. 150 crore CAPEX planned for expanding Xanthine production capacity from 5000 to 9000 metric tonnes across two sites, expected completion by early FY26. - **Atali Project:** Rs. 375 crore outlay for Atali facility focused on CDMO/CMO and Intermediate manufacturing, expected to commission by Q4 FY25; will add 400–500 KL capacity, increasing overall capacity by 25-30%. - **Vapi Site Expansion:** Semi-commercial block for small to medium batch sizes commissioning expected in Q2 FY25 to support early phase CDMO/CMO projects. - **Solar Power Plant:** Rs. 90 crore investment in a new solar power plant at Akola, Maharashtra, expected to commission in the current quarter and cover one-third of power requirements, reducing manufacturing costs. - **Total FY25 CAPEX:** Estimated Rs. 500-550 crore encompassing the above projects. These investments aim to drive capacity expansion, support CDMO business growth, and improve cost efficiencies.

Track Aarti Pharma — get its next earnings analysis in your feed

How does Aarti Pharma rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisAarti Pharma
Rev 2Mar 3

How does Aarti Pharma rank in Pharmaceuticals & Biotechnology?

Compare Aarti Pharma against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →